Literature DB >> 18617911

Measurement of fornix depth and area: a novel method of determining the severity of fornix shortening.

T Kawakita1, M Kawashima, D Murat, K Tsubota, J Shimazaki.   

Abstract

PURPOSE: To measure the depth and area of the fornix in normal adults and patients with symblepharon.
METHODS: The fornix depth of normal eyes (n=20) and patients with symblepharon (Stevens-Johnson syndrome, n=4) was measured at six locations in each eye using non-invasive, dull-edged stainless steel metric scale. Before and after conjunctival reconstruction surgery, the depths of fornix were also measured by the same method. The overall area was assessed from those fornix depth at six points.
RESULTS: The mean depths of the superior nasal and temporal, inferior nasal and temporal, fornices as well as mean depths of medial nasal and temporal canthi fornices in normal eyes were 14.1+/-2.5, 14.1+/-2.5, 10.0+/-2.1, 10.4+/-1.8, 3.0+/-0.9, and 5.2+/-1.2 mm, respectively. The mean overall area of the conjunctival fornix in normal subjects was 909.6+/-162.2 mm(2). All these parameters were significantly lower in the eyes of patients. Both depth and area after surgery were significantly deeper and larger than before.
CONCLUSIONS: This estimation may prove useful when evaluating the severity of symblepharon and determining the post-surgical prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 18617911     DOI: 10.1038/eye.2008.205

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  9 in total

1.  [Late complications after chemical burns of the ocular surface. Surgical strategies for ocular surface reconstruction].

Authors:  B Bachmann; C Cursiefen
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

2.  Upper and lower conjunctival fornix depth in healthy white caucasian eyes: a method of objective assessment.

Authors:  G Jutley; D Carpenter; S Hau; D Booth; H A Jasim; E Tay; C Daniel; V Saw
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

3.  Ocular and oral grading of mucous membrane pemphigoid.

Authors:  Graham M B Reeves; Marianne Lloyd; Bijaya P Rajlawat; Gillian L Barker; E Anne Field; Stephen B Kaye
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-13       Impact factor: 3.117

Review 4.  Molecular mechanisms and treatments for ocular symblephara.

Authors:  Aditi Swarup; Christopher N Ta; Albert Y Wu
Journal:  Surv Ophthalmol       Date:  2021-04-29       Impact factor: 6.048

5.  Validation of a fornix depth measurer: a putative tool for the assessment of progressive cicatrising conjunctivitis.

Authors:  Geraint P Williams; Valerie P J Saw; Tariq Saeed; Simon T Evans; Paul Cottrell; S John Curnow; Peter Nightingale; Saaeha Rauz
Journal:  Br J Ophthalmol       Date:  2010-10-17       Impact factor: 4.638

6.  Defining the limits of normal conjunctival fornix anatomy in a healthy South Asian population.

Authors:  Imran J Khan; Abdul-Jabbar Ghauri; James Hodson; Matthew R Edmunds; Paul Cottrell; Simon Evans; Geraint P Williams; Saaeha Rauz
Journal:  Ophthalmology       Date:  2013-12-04       Impact factor: 12.079

Review 7.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

Review 8.  Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment.

Authors:  Panagiotis Georgoudis; Francesco Sabatino; Nora Szentmary; Sotiria Palioura; Eszter Fodor; Samer Hamada; Hendrik P N Scholl; Zisis Gatzioufas
Journal:  Ophthalmol Ther       Date:  2019-01-29

9.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.